Quantro Therapeutics & IMP Enter Research Collaboration to Accelerate Transcriptomic Drug Discovery

Overview

Quantro Therapeutics, a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company is entering into a strategic research collaboration with the group of Dr. Johannes Zuber, a world-leading expert in functional genetics and one of the co-founders of Quantro, at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria. The goal of the collaboration is to investigate the molecular functions of transcription factor complexes that have emerged as promising targets for the development of cancer therapies.

Transcription Factors & Other Things About Cancer Cells

• Cancer cells depend on specific transcription factors – proteins that regulate gene expression – to maintain their abnormal behaviour. 
• While transcription factors have long been considered “undruggable”, new molecules have been found that trigger their degradation or disrupt interactions with essential co-factors. 
• These advances have led to major breakthroughs in the treatment of some cancer types. 
• However, existing drugs targeting transcription have often been found only through serendipity, while their systematic discovery and development have been hampered by a lack of scalable methods to directly measure transcriptional activity. 
• The new collaboration focuses on expanding Quantro’s transcriptomic discovery approach by integrating genetic screening technologies to gain a deeper understanding of how transcription factors interact with co-factors and other regulatory proteins. 
• The Zuber lab at the IMP has developed advanced genetic screening and validation assays to identify and characterize such key co-factors and regulators, thereby complementing Quantro’s activities building an innovative proprietary transcription factor targeting R&D pipeline.

Words from Group Leader at IMP

Dr. Johannes Zuber, group leader at the IMP, commented: “A detailed understanding of protein binding partners is essential for developing new drugs and refining existing hits. While finding compounds that bind to transcription factors is relatively straightforward, it is often unclear whether this binding event interferes with co-factor interactions or other critical protein functions. Quantro’s time-resolved transcriptomics technology can answer this question with unprecedented precision, and our genetic screens can pinpoint the relevant co-factors.”

Words from the CEO: Quantro

• Dr. Michael Bauer, CEO of Quantro, added: “Our transcriptomic discovery platform addresses one of drug discovery’s greatest challenges - making previously ‘undruggable’ targets accessible. With our proprietary technology, we can instantly detect transcriptional changes with high precision, enabling us to focus on direct and immediate transcriptional responses. 
• This partnership will further strengthen our capabilities and understanding of the biology of the targets we are working on by integrating the IMP’s exceptional research expertise and by providing access to complementary know-how and resources. Together, we aim to accelerate drug discovery for currently untreatable diseases.

About the Company: Quantro Therapeutics

Quantro Therapeutics is a transcriptomic drug discovery and R&D company focused on building a highly innovative pipeline of modulators, inhibitors or degraders of transcription factors, transcriptional regulators and cell signalling targets.

About Research Institute of Molecular Pathology

• The Research Institute of Molecular Pathology (IMP) in Vienna is a basic life science research institute largely sponsored by Boehringer Ingelheim. 
• With over 200 scientists from 40 countries, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. 
• The IMP is part of the Vienna BioCenter, one of Europe’s most dynamic life science hubs with 2,800 people from over 80 countries in six research institutions, two universities, and 40 biotech companies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!